Recent news
July 2010
Priority review vouchers for neglected diseases need support, blog says
The US Food and Drug Administration’s priority review voucher (PRV) program is "moving forward very quickly, but long product development timelines dictate that it will take time to blossom," a BIO Ventures for Global Health blog says. The FDA’s PRV program awards a voucher to the sponsor of a newly approved drug or biologic that targets a neglected tropical disease. The voucher entitles the bearer to a priority review for any future new drug application. According to the blog, the PRV program is still in the "nascent stages" and needs support from the FDA, companies, and advocates. See the blog for more details.
